Skip to main content
Biosimilars
Real-World Utilization of Infliximab and Its Biosimilars in Rheumatoid Arthritis
Read More
Biosimilars
Use of Multibiomarker Disease Activity Scores to Compare Biosimilar Adalimumab-afzb with EU-Sourced Reference Adalimumab in Patients with Active RA
Read More
Biosimilars
Switching to SB5 Biosimilar from Reference Adalimumab in Patients with RA, Axial Spondyloarthritis, or Psoriatic Arthritis
Read More
Biosimilars
Adalimumab Biosimilar PF-06410293 versus Reference Adalimumab in Patients with Moderate-to-Severe, Active Rheumatoid Arthritis
Read More
Biosimilars
Efficacy and Safety Equivalence of Proposed High-Concentration Adalimumab Biosimilar to Reference Adalimumab in Moderate-to-Severe, Active RA
Read More
Biosimilars
Switching to SB4 versus Continuation of Etanercept Reference in Patients with Rheumatoid Arthritis and Low Disease Activity
Read More
Biosimilars
Impact of Successive Switches of 2 Different Etanercept Biosimilars on Outcomes in Inflammatory Rheumatic Diseases
Read More
Biosimilars
Comparative Safety Analysis of Infliximab with Its Biosimilar Infliximab-dyyb in Pediatric Rheumatic Conditions
Read More
Biosimilars
Multibiomarker Disease Activity Scores as a Biosimilarity Assessment to Compare Biosimilar Infliximab-qbtx with Infliximab-EU in Patients with Active RA
Read More
Biosimilars
Phase 3 TROIKA Results Demonstrate Clinical Similarity Between HD201 and Trastuzumab Reference in HER2-Positive Early Breast Cancer
Read More
Page 111 of 197
Results 1101 - 1110 of 1963